Alterations in human trabecular meshwork cell homeostasis by selenium

被引:13
作者
Conley, SM
McKay, BS
Gandolfi, AJ
Stamer, WD
机构
[1] Univ Arizona, Dept Ophthalmol, Tucson, AZ 85711 USA
[2] Univ Arizona, Dept Cell & Mol Biol, Tucson, AZ 85711 USA
[3] Univ Arizona, Dept Pharmacol & Ophthalmol, Tucson, AZ 85711 USA
[4] Univ Arizona, Dept Pharmacol & Toxicol, Tucson, AZ 85711 USA
关键词
D O I
10.1016/j.exer.2005.08.024
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Epidemiological evidence indicates that selenium supplementation may increase risk for glaucoma and ocular hypertension. The purpose of this study was to determine the effects of selenium on trabecular meshwork cells, a likely site of pathology for glaucoma. Human trabecular meshwork (HTM) cells and human umbilical vein endothelial cells (HUVECs) were treated with selenium (MSeA) at or near physiologically relevant concentrations. Selenium uptake by cells was monitored using mass spectrometry. Alterations in protein secretion, intracellular signaling, and cell morphology were monitored; and the role of integrin signaling in MSeA-induced morphological alterations was investigated using divalent cation treatments. Radiolabeling was used to assess protein synthesis and secretion, while luciferase and MTT assays monitored total cellular ATP and cell viability, respectively. Whereas detectible changes in intracellular selenium were observed after exposure to 1-10 AM MSeA for 24 hr, the majority remained in the conditioned medium. Selenium-induced morphological changes (<= 3 hr) occurred before alterations in protein secretion and intracellular signaling (3-6 hr). Zinc treatment prevented selenium-mediated alterations in protein secretion and changes in cell-matrix adhesion. MSeA treatment (5 mu M) led to a 60% decrease in protein synthesis after 3 hr and a 30% reduction in secretion, although significant alterations in cell viability and total ATP were not observed after MSeA treatment. Selenium altered several indicators of HTM cell homeostasis, but did not affect viability at physiologically relevant doses. Similar results with HUVECs have implications for understanding selenium's mechanisms of action as an anti-angiogenic agent. (c) 2005 Elsevier Ltd. All rights reserved.
引用
收藏
页码:637 / 647
页数:11
相关论文
共 33 条
[1]  
ACOTT TS, 1992, TRABECULAR EXTRACELL, P125
[2]  
ALVARADO J, 1984, OPHTHALMOLOGY, V91, P564
[3]  
[Anonymous], 2002, SELENIUM SUPPLEMENTA
[4]   Pharmacologic disruption of Schlemm's canal cells and outflow facility in anterior segments of human eyes [J].
Bahler, CK ;
Hann, CR ;
Fautsch, MP ;
Johnson, DH .
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2004, 45 (07) :2246-2254
[5]  
Chavakis T, 1999, BLOOD, V93, P2976
[6]   Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin a randomized controlled trial - A randomized controlled trial [J].
Clark, LC ;
Combs, GF ;
Turnbull, BW ;
Slate, EH ;
Chalker, DK ;
Chow, J ;
Davis, LS ;
Glover, RA ;
Graham, GF ;
Gross, EG ;
Krongrad, A ;
Lesher, JL ;
Park, HK ;
Sanders, BB ;
Smith, CL ;
Taylor, JR .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1996, 276 (24) :1957-1963
[7]   Selenium's effects on MMP-2 and TIMP-1 secretion by human trabecular meshwork cells [J].
Conley, SM ;
Bruhn, RL ;
Morgan, PV ;
Stamer, WD .
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2004, 45 (02) :473-479
[8]  
EPSTEIN DL, 1997, CHANDLER GRANTS GLAU, P680
[9]   Selenium and signal transduction: Roads to cell death and anti-tumour activity [J].
Ghose, A ;
Fleming, J ;
Harrison, PR .
BIOFACTORS, 2001, 14 (1-4) :127-133
[10]  
Jiang C, 1999, MOL CARCINOGEN, V26, P213, DOI 10.1002/(SICI)1098-2744(199912)26:4<213::AID-MC1>3.0.CO